AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00084123 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard Care
Study NCT04667351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2400 mg/m² 5-fu
Description: Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
Study NCT04667351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200 mg/m² 5-fu
Description: Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
Study NCT02103569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of Daclatasvir, Asunaprevir and BMS-791325
Study NCT02103569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of Norethindrone and Ethinyl Estradiol
Study NCT02103569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT02872766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CXL Myopia
Description: Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
Study NCT04578795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single use flexible ureteroscopy (PUSEN-OLIMPUS)
Description: single use flexible ureteroscopy
Study NCT03289650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: immunosuppressive agent tacrolimus, given twice-daily
Study NCT03289650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Extended Release Oral Tablet [Envarsus]
Description: immunosuppressive agent extended-release tacrolimus, given once daily
Study NCT03325673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear
Description: TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
Study NCT03325673 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TrueTear Sham Control
Description: TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
Study NCT05448872 — intervention group
Intervention type: DRUG
Intervention: Sacubitril/Valsartan
Description: HF patients treated with Sac/Val
Study NCT04479163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: 250 ml Convalescent plasma with an IgG titer against SARS CoV2
Study NCT04479163 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9%
Study NCT00748579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
Study NCT00748579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
Study NCT02025426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Study NCT02025426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Study NCT00789529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free® RepleniSH® MPDS
Description: soft contact lens disinfecting solution
Study NCT00789529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus®
Description: soft contact lens disinfecting solution
Study NCT03695003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cognivia
Description: Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira
Study NCT03695003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
Study NCT01262365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
Study NCT01262365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
Study NCT01262365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Study NCT01262365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Study NCT01817309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endotoxin assay in peritoneal dialysis effluent
Description: endotoxin level by Limulus Amebocyte Lysate (LAL) assay
Study NCT00820898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01000662 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Daily Radiation Therapy
Description: 15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
Study NCT01000662 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Radiation Therapy
Description: 15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
Study NCT02289183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy
Description: Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
Study NCT02289183 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy
Description: Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
Study NCT00753870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCRE inhalation
Description: 20,000 EU CCRE given as a one-time challenge
Study NCT02230631 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Two different questionnaires will be applied to patients during a regular clinical visit.
Study NCT01280136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: It's Your Game Tech
Description: An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game...Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
Study NCT00639249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration
Study NCT00639249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA4503 Low
Description: Oral administration
Study NCT00639249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA4503 High
Description: Oral administration
Study NCT02646982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo will be given once daily for 12 months.
Study NCT02646982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP>100 mm Hg, DBP>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
Study NCT01671852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
Study NCT01671852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03891940 — intervention group
Intervention type: PROCEDURE
Intervention: patients recieving anterior cervical spine surgery
Description: Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
Study NCT01049841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine + temsirolimus
Description: The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
Study NCT01594853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
Study NCT02027103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
Study NCT02027103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
Study NCT01248351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous stored platelets
Description: Administration of autologous stored platelets
Study NCT01248351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: administration of autologous stored platelets
Description: administration of autologous stored platelets
Study NCT01248351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous stored platelets
Description: transfusion of autologous stored platelets
Study NCT03655613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APL-501
Description: Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
Study NCT03655613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: Oral specific c-Met inhibitor
Study NCT03655613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Fully human IgG4 monoclonal antibody against PD-1
Study NCT04006964 — intervention group
Intervention type: DEVICE
Intervention: Resmon PRO FULL v2
Description: Measurement of lung impedance by the Forced Oscillation Technique
Study NCT04989920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group: CIMT group (Constraint-Induced Movement Therapy)
Description: 2 weeks of intensive therapy delivered 5d/week for 6 hrs/day
Study NCT01854619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photodisinfection (antimicrobial photodynamic therapy, aPDT)
Description: A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
Study NCT01854619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline irrigation
Description: The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
Study NCT01676714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Study NCT01489839 — intervention group
Intervention type: OTHER
Intervention: Periodontal therapy
Description: All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
Study NCT03559855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real Essentials
Description: The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
Study NCT04034160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegetarian burger
Description: A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 1 will be given vegetarian burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched.
Study NCT04034160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: beef burger
Description: A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 2 will be given beef burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched.
Study NCT04788355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group (standard hospital treatment)
Description: Medications defined by the hospital involved in the study
Study NCT04788355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group (standard hospital treatment)
Description: Medications defined by the hospital involved in the study
Study NCT04788355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group Hydroxychloroquine
Description: Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.
Study NCT04788355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group Hydroxychloroquine and apixaban
Description: Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
Study NCT04788355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group Apixaban
Description: Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
Study NCT00872105 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-operative Treatment
Description: Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
Study NCT00872105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Treatment
Description: The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)
Study NCT02698735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
Study NCT02698735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
Study NCT04485520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARICA PAPAYA MOUTHWASH
Description: Each application was 10 ml. applied for 1 minute, once a day for 8 days
Study NCT04485520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHLORHEXIDINE MOUTHWASH
Description: Each application was 10 ml. applied for 1 minute, once a day for 8 days
Study NCT01094769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
Study NCT01094769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose capsule taken once daily
Study NCT00887237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT with triple site ventricular stimulation
Description: CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
Study NCT00887237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cardiac resynchronization
Description: Conventional cardiac resynchronization
Study NCT01294670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat and Etoposide
Description: Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
Study NCT01871974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: oral
Study NCT03490305 — intervention group
Intervention type: PROCEDURE
Intervention: Exploratory laparotomy
Description: Findings and procedures done at exploratory laparotomy
Study NCT00661531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrace
Description: Estrace 10 mg three times daily will be administered for 3 months.
Study NCT00661531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
Study NCT03405259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super Seal® Desensitizer
Description: Single dose professional application.
Study NCT03405259 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acclean® Fluoride Varnish
Description: Single dose professional application.
Study NCT01146873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Children are assigned to begin a EFV-based antiretroviral based regimen.
Study NCT01146873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Description: Children are assigned to stay on their current LPV/r-based antiretroviral regimen.